Identification of FDA-approved drugs that increase mevalonate kinase in hyper IgD syndrome

被引:1
|
作者
Politiek, Frouwkje A. [1 ,2 ]
Turkenburg, Marjolein [1 ]
Koster, Janet [1 ]
Ofman, Rob [1 ]
Waterham, Hans R. [1 ,2 ,3 ,4 ]
机构
[1] Amsterdam Univ Med Ctr, Acad Med Ctr, Dept Lab Med, Lab Genet Metab Dis, Amsterdam, Netherlands
[2] Amsterdam Gastroenterol Endocrinol & Metab, Amsterdam, Netherlands
[3] Amsterdam Reprod & Dev, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
cholesterol biosynthesis; clobetasol propionate; glucocorticoids; mevalonate kinase deficiency; systemic autoinflammatory diseases; HYPERIMMUNOGLOBULINEMIA-D; CHOLESTEROL; DEFICIENCY; MUTATIONS; PHENOTYPE; SERIES; BIOSYNTHESIS; GENOTYPE; SPECTRUM; CELLS;
D O I
10.1002/jimd.12698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi-allelic loss-of-function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early-lethal mevalonic aciduria to the milder hyper-IgD syndrome (MKD-HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD-HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non-sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD-HIDS patients less sensitive to developing inflammatory episodes, we established a cell-based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD-HIDS variant, MK-V377I, C-terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library (R), which includes 1280 FDA-approved compounds. Multiple compounds increased MK-V377I-nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK-V377I-nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD-HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element-binding protein 2 (SREBP-2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP-2 could be a potential therapeutic strategy in MKD-HIDS.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 50 条
  • [1] Hyper-IgD syndrome or mevalonate kinase deficiency
    Stoffels, Monique
    Simon, Anna
    CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (05) : 419 - 423
  • [2] Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?
    C. M. Mulders-Manders
    A. Simon
    Seminars in Immunopathology, 2015, 37 : 371 - 376
  • [3] Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?
    Mulders-Manders, C. M.
    Simon, A.
    SEMINARS IN IMMUNOPATHOLOGY, 2015, 37 (04) : 371 - 376
  • [4] Identification of FDA-approved drugs that induce heart regeneration in mammals
    Mahmoud Salama Ahmed
    Ngoc Uyen Nhi Nguyen
    Yuji Nakada
    Ching-Cheng Hsu
    Ayman Farag
    Nicholas T. Lam
    Ping Wang
    Suwannee Thet
    Ivan Menendez-Montes
    Waleed M. Elhelaly
    Xi Lou
    Ilaria Secco
    Mateusz Tomczyk
    Lorena Zentilin
    Jimin Pei
    Miao Cui
    Matthieu Dos Santos
    Xiaoye Liu
    Yan Liu
    David Zaha
    Gregory Walcott
    Diana R. Tomchick
    Chao Xing
    Cheng Cheng Zhang
    Nick V. Grishin
    Mauro Giacca
    Jianyi Zhang
    Hesham A. Sadek
    Nature Cardiovascular Research, 2024, 3 : 372 - 388
  • [5] Identification of FDA-Approved Drugs That Induce Heart Regeneration in Mammals
    Nguyen, Ngoc U.
    Ahmed, Mahmoud S.
    Nakada, Yuji
    Hsu, Ching-Cheng
    Farag, Ayman
    Wang, Ping
    Menendez-Montes, Ivan
    Thet, Suwannee
    Lam, Nicholas T.
    Tomchick, Diana R.
    Walcott, Gregory
    Grishin, Nick V.
    Zhang, Jianyi J.
    Sadek, Hesham A.
    CIRCULATION RESEARCH, 2022, 131 (12) : E171 - E171
  • [6] Identification of FDA-approved drugs that induce heart regeneration in mammals
    Ahmed, Mahmoud Salama
    Nguyen, Ngoc Uyen Nhi
    Nakada, Yuji
    Hsu, Ching-Cheng
    Farag, Ayman
    Lam, Nicholas T.
    Wang, Ping
    Thet, Suwannee
    Menendez-Montes, Ivan
    Elhelaly, Waleed M.
    Lou, Xi
    Secco, Ilaria
    Tomczyk, Mateusz
    Zentilin, Lorena
    Pei, Jimin
    Cui, Miao
    Dos Santos, Matthieu
    Liu, Xiaoye
    Liu, Yan
    Zaha, David
    Walcott, Gregory
    Tomchick, Diana R.
    Xing, Chao
    Zhang, Cheng Cheng
    Grishin, Nick V.
    Giacca, Mauro
    Zhang, Jianyi
    Sadek, Hesham A.
    NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (3): : 372 - 388
  • [7] Identification of FDA-approved drugs targeting the Farnesoid X Receptor
    van de Wiel, Sandra M. W.
    Bijsmans, Ingrid T. G. W.
    van Mil, Saskia W. C.
    van de Graaf, Stan F. J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] Identification of FDA-approved drugs targeting the Farnesoid X Receptor
    Sandra M. W. van de Wiel
    Ingrid T. G. W. Bijsmans
    Saskia W. C. van Mil
    Stan F. J. van de Graaf
    Scientific Reports, 9
  • [9] Safety of FDA-Approved drugs - Reply
    Friedman, MA
    Woodcock, J
    Lumpkin, MM
    Shuren, JE
    Hass, AE
    Thompson, LJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24): : 2297 - 2298
  • [10] NONAPPROVED USES OF FDA-APPROVED DRUGS
    ANDERSON, BJ
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 211 (10): : 1705 - &